Pembrolizumab was selected over other ICIs based on the breast tumor’s PD-L1 CPS > 10, which suggested favorable response to immunotherapy, and the more extensive literature supported pembrolizumab use across multiple tumor types (3, 5, 11). The gene discussed is CD274; the disease is breast neoplasm.